APR 08, 2018 01:31 PM PDT
A New Type of Antibiotic has Been Found
WRITTEN BY: Carmen Leitch
3 71 3990

Now that people are facing a crisis from the rise of antibiotic-resistant bacteria, there has been considerable research interest in identifying new drug candidates to help stem the problem (learn more about the issue from the video). Now, an international team of researchers has reported the discovery of a new class of antibiotics, called odilorhabins or ODLs, which are made by bacteria that live within nematode worms. These new molecules have a unique way of killing bacteria, which may also be useful for eliminating bacteria that carry drug resistance genes. The work, reported in Molecular Cell by investigators at the University of Illinois at Chicago and Nosopharm, a Lyon, France biotechnology company, outlines the antibiotic as well as its mode of action.

These symbiotic bacteria that produce the antibiotic are not well understood. The Nosopharm scientists assessed 80 strains of it to look for antimicrobial characteristics. Compounds that displayed activity were then isolated, and the researchers could study the structure of those compounds. Derivatives that were even more powerful could then be created.

Corresponding authors Alexander Mankin and Yury Polikanov of UIC led the study on the drug's mechanism of action. ODLs exert their effect on an organelle called the ribosome, which builds proteins for the cell, and in this case, the bacterium.

"Like many clinically useful antibiotics, ODLs work by targeting the ribosome, but ODLs are unique because they bind to a place on the ribosome that has never been used by other known antibiotics” explained Polikanov, assistant professor of biological sciences in the UIC College of Liberal Arts and Sciences.

ODLs (yellow) bind to a site on the ribosome not used by other antibiotics. Location of this site is shown here relative to the sites of other known antibiotics, such as negamycin (green), tetracycline (dark blue), aminoglycoside antibiotic paromomycin (red) and streptomycin (light blue). / Credit: UIC/Yury Polikanov, et al

"When ODLs are introduced to the bacterial cells, they impact the reading ability of the ribosome and cause the ribosome to make mistakes when it creates new proteins," said Mankin, director of the Center for Biomolecular Sciences in the UIC College of Pharmacy. "This miscoding corrupts the cell with flawed proteins and causes the bacterial cell to die."

Many antibiotics act to slow the growth of bacteria, and Mankin noted that antibiotics that kill bacteria directly, bactericidal antibiotics, are unusual.

"The bactericidal mechanism of ODLs and the fact that they bind to a site on the ribosome not exploited by any known antibiotic are very strong indicators that ODLs have the potential to treat infections that are unresponsive to other antibiotics," said Mankin.

The Nosopharm team assessed how well the ODL compounds acted on bacterial pathogens, including strains that are known to develop resistance.

"We found that the ODL compounds cured mice infected with several pathogenic bacteria and demonstrated activity against both Gram-negative and Gram-positive pathogens, notably including carbapenem-resistant Enterobacteriaceae," revealed co-corresponding author Maxime Gualtieri, co-founder and chief scientific officer of Nosopharm. (Learn more about these deadly bacteria from the following video.)

The researchers think that this work highlights the value of international collaboration when confronted with serious problems. "In this case, the combined expertise of the industry, which has the resources to develop new compounds, and the academia, which has the research and lab capabilities to understand how the compounds work, have enabled the development of this new class of antibiotics," Mankin noted.

"The collaboration between multiple labs with diverse areas of expertise add credibility to the research," Polikanov added.

A lot of work remains; the therapeutic potential and possible drawbacks of ODL have to be assessed thoroughly, but these findings show that such a study is warranted.
"Collaborations with academia with renown expertise in antibiotics like the UIC team help us for this preclinical development," said Philippe Villain-Guillot, co-founder and chief executive officer of Nosopharm.

These are UIC's (left to right) Alexander Mankin, Tanja Florin, Malgorzata Dobosz-Bartoszek, Yury Polikanov. / Credit: UIC/Jenny Fontaine

Sources: AAAS/Eurekalert! Via University of Illinois, Molecular Cell

About the Author
  • Experienced research scientist and technical expert...
You May Also Like
APR 30, 2018
Clinical & Molecular DX
APR 30, 2018
Reducing Dependency on Antibiotics in Hospitals
How can small community and rural hospitals create antibiotic stewardship programs to reduce the danger of antibiotic resistance? Scientists from the Inter
MAY 21, 2018
MAY 21, 2018
Common Antibacterial Chemical may Help Fight Lung Infections
New research has found when triclosan is used with another FDA-approved drug, it can help fight deadly illness.
MAY 22, 2018
MAY 22, 2018
Breakthrough Analysis Outlines Conceivable Cause of Childhood ALL
A team from the Institute of Cancer Research has published a comprehensive literature review and outlined a breakthrough in the causative theory of childhood ALL development.
MAY 29, 2018
MAY 29, 2018
Environmental Factors Drive Belly Fat Buildup
Abdominal fat is a major risk factor for disease. New work could help find those at risk for increased belly fat, and help reverse that trend.
JUL 04, 2018
JUL 04, 2018
How Did Viruses Originate?
There is still a debate about whether or not viruses are a form of life, and we really don't know where they came from.
JUL 11, 2018
JUL 11, 2018
New Insight Into Bacterial Pathogenicity
Scientists have learned how some pathogenic bacteria stick to cells in the intestine, which gets their infection started.
Loading Comments...